



**EXPEDITED PROCEDURE  
RESPONSE UNDER 37 C.F.R. § 1.116  
GROUP ART UNIT: 1646**

**PATENT**  
Customer No. 22,852  
Attorney Docket No. 3495.0187-00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: ) **ATTN: BOX FINAL**  
)  
COEN et al. ) Group Art Unit: 1646  
)  
Serial No.: 09/501,787 ) Examiner: M. Brannock, Ph.D.  
)  
Filed: February 11, 2000 )  
)  
For: HYBRID TETANUS TOXOID )  
PROTEINS THAT MIGRATE )  
RETROGRADELY AND )  
TRANSYNAPTICALLY INTO )  
THE CNS )

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT AND RESPONSE**  
**UNDER 37 C.F.R. § 1.116 TO PAPER NO. 13**

In response to the Final Office Action dated June 18, 2002 (Paper No. 13), the period for reply having been extended by a petition for extension of time and fee payment filed concurrently herewith, and pursuant to 37 C.F.R. § 1.116, applicants submit the following remarks and propose that the application be amended as follows.

**IN THE CLAIMS:**

Please amend claim 31 as follows:

31. (Amended Two Times) A method for treating a central nervous system (CNS) disease comprising:

TECH CENTER 1600/2900

DEC 20 2002

RECEIVED

15/D  
D. J.  
1/13/03  
NE

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com